Pertuzumab as second‑ or later‑line therapy for human epidermal growth factor receptor 2‑positive metastatic breast cancer: A clinical experience

Trastuzumab and pertuzumab with taxane-based chemotherapy are considered the first-line standard therapy for human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (mBC). Pertuzumab is also a later-line therapy for mBC in Switzerland, although limited safety and efficacy d...

Descripción completa

Detalles Bibliográficos
Autores principales: Biskup, Ewelina, Sartorius, Céline Montavon, Müller, Andreas, Leo, Cornelia, Nussbaum, Catrina Uhlmann, Georgescu Margarint, Elena Laura, Koychev, Daniel, Schreiber, Alexander, Taverna, Christian, Thorn, David, Vetter, Marcus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251341/
https://www.ncbi.nlm.nih.gov/pubmed/37303973
http://dx.doi.org/10.3892/mco.2023.2648

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251341/
https://www.ncbi.nlm.nih.gov/pubmed/37303973
http://dx.doi.org/10.3892/mco.2023.2648

Ejemplares similares